The double upgrade from Argus aligns with a strongly bullish consensus and positive EPS revision momentum, but significant insider selling and institutional trimming create a conflicting signal. The setup is constructive but warrants caution given the divergence between analyst optimism and insider behavior.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
Price Chart
Executive Summary
Argus Research issued a double upgrade on Regeneron Pharmaceuticals (REGN) on October 1, 2026, raising its rating from Hold to Buy with a new price target of $850. The stock currently trades at $758.27, implying approximately 12.1% upside to the new target. Argus has a 54% accuracy rate on 377 scored calls with an average return of 3.3%, placing it in the middle of the pack among firms covering REGN. The consensus on REGN is heavily bullish, with 26 analysts split at 100% Buy (26 Buy/Strong Buy) and 0% Hold or Sell. The mean price target is $850.88, nearly identical to Argus's $850 target, indicating this call is closely aligned with consensus. Momentum is positive, with 1 upgrade and 0 downgrades in the past 30 days, and EPS estimates for the current fiscal year have seen 23 upward revisions versus 0 downward revisions over the same period. Insider selling has been notable, with five transactions totaling over $3.3 million in August and September 2026, while institutional activity shows significant trimming by major holders. The next earnings report is due October 30, 2026, adding a near-term catalyst. Overall, the double upgrade reinforces the bullish consensus but is partially offset by insider selling and institutional exits.
Impact Score
Consensus & Targets
The consensus among 26 analysts covering REGN is overwhelmingly bullish: 8 Strong Buy, 18 Buy, 12 Hold, 0 Sell, 0 Strong Sell. This translates to 100% Buy/Strong Buy and 0% Hold/Sell, making the consensus direction strongly positive. Argus's upgrade aligns with this bullish consensus.
The current price is $758.27. The mean price target is $850.88, median $857, high $1,030, and low $730. The implied upside to the mean is 12.2%. Argus's $850 target is slightly below the mean and median, placing it in the middle of the consensus range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-01 | Argus Research | upgrade | Buy | $850.00 |
| 2026-09-29 | RBC Capital | reiterate | Sector Perform | $737.00 |
| 2026-09-10 | HSBC | maintain | Buy | $920.00 |
| 2026-08-17 | Leerink Partners | maintain | Market Perform | $824.00 |
| 2026-08-03 | Citigroup | maintain | Neutral | No target |
| 2026-08-03 | Guggenheim | maintain | Buy | $1,030.00 |
| 2026-07-31 | RBC Capital | maintain | Sector Perform | $737.00 |
| 2026-07-31 | Morgan Stanley | maintain | Equal-Weight | $758.00 |
| 2026-07-31 | Cantor Fitzgerald | maintain | Overweight | $795.00 |
| 2026-07-31 | Wells Fargo | maintain | Equal-Weight | $750.00 |
In the past 30 days, there has been 1 upgrade (Argus) and 0 downgrades. EPS revision trends are strongly positive: for the current fiscal year (0y), there have been 23 upward revisions and 0 downward revisions in the past 30 days. Estimates are being revised higher across all near-term periods, supporting the bullish analyst momentum.
Firm Track Record: Argus Research
Argus Research accuracy: 54% on 377 calls | avg return: 3.3%
Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| UBS | 67% | 4/6 | 5.1% | top tier |
| Canaccord Genuity | 57% | 4/7 | 9.4% | above average |
| TD Cowen | 50% | 1/2 | 3.1% | below average |
| Bernstein | 50% | 1/2 | 6.2% | below average |
| Cantor Fitzgerald | 50% | 4/8 | -4.5% | below average |
| BMO Capital | 50% | 3/6 | -3.7% | below average |
| Morgan Stanley | 50% | 5/10 | 4.1% | below average |
| Goldman Sachs | 50% | 1/2 | -3.6% | below average |
| Leerink Partners | 50% | 1/2 | -23.7% | below average |
| Evercore ISI Group | 50% | 1/2 | -4.9% | below average |
Argus Research has a 54% accuracy rate on 377 scored calls with an average return of 3.3%. This places it in the middle tier among firms covering REGN. The best-performing firm is Canaccord Genuity (57% accuracy, 9.4% avg return), while the worst is Leerink Partners (50% accuracy, -23.7% avg return). Argus's accuracy is slightly above the average of the firms listed.
Earnings Estimates
Next earnings: Oct 30, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $15.53 | $10.47 to $18.62 | $4.6B | ↑0 ↓0 |
| 0q | $15.94 | $14.53 to $17.68 | $4.5B | ↑0 ↓0 |
| 0y | $54.10 | $43.42 to $59.45 | $17.0B | ↑2 ↓0 |
| +1y | $50.63 | $42.52 to $57.25 | $18.5B | ↑0 ↓0 |
Cross-Platform Signals
Insider trading shows five sell transactions in August-September 2026 totaling over $3.3 million, including sales by directors McCourt Marion and Zoghbi Huda Y. This selling diverges from the bullish analyst signal. Institutional activity shows significant trimming: T. Rowe Price trimmed 29.8%, Capital World Investors trimmed 42.6%, and Capital Research Global Investors exited completely. One small institutional add was noted. Congressional activity shows a buy by Rep. Ro Khanna in July 2026. Short interest data is not available. Overall, the insider and institutional signals diverge from the bullish analyst consensus.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers